Drug Trial Radar · NCT00129298
Effectiveness of Tiagabine for Cocaine Dependence in Methadone-Maintained Individuals - 1
Last checked: Nov 19, 2026Latest source record: Jan 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Dec 2004
Primary completion
Not stated
Study completion Apr 2007
Sponsor
- Lead sponsor
- National Institute on Drug Abuse (NIDA)NIH
- Sponsor type
- NIH
- First posted
- Aug 11, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Many opioid-dependent individuals are also dependent on cocaine. Methadone is a widely used and effective method for treating opioid dependence. However, it is not effective in treating other drugs of abuse. The purpose of this study is to determine the effectiveness of another drug, tiagabine, for treating cocaine dependence in opioid-dependent individuals already receiving methadone treatment.
Conditions
- Cocaine-Related Disorders
- Opiate Dependence
Interventions
TiagabineDrug
The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thrice weekly Urine toxicologyTime frame: 13 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.